Investment Rating - The investment rating for Dicker Data Ltd is Overweight (OW) with a price target of A$10.30, indicating a potential upside of 20% from the current price of A$8.60 [2][4]. Core Insights - The report highlights a constructive outlook for the second half of the year, despite a modest shortfall in year-to-date profitability. The financial results are seen as reinforcing a skew towards stronger performance in the latter half of the year [1][4]. - Revenue growth is projected to be strong at 17%, which is an acceleration compared to the approximately 10% growth noted in previous calls. However, gross profit growth is only at 5%, indicating potential challenges in margin expansion [7]. - The report notes that the company is likely to face headwinds from a higher mix of lower-margin enterprise products and challenges in product mix, particularly with PCs and infrastructure hardware [7][8]. Financial Metrics Summary - For the fiscal year ending December 2024, the estimated revenue is A$3,363 million, with projected growth to A$4,003 million by December 2027. EBITDA is expected to grow from A$150 million in 2024 to A$188 million in 2027 [4]. - Earnings per share (EPS) are projected to increase from A$0.45 in 2024 to A$0.57 in 2027, reflecting a positive trend in profitability [4]. - The report indicates a P/E ratio decreasing from 18.6 in 2025 to 15.0 in 2027, suggesting improving valuation metrics over time [4]. Valuation Methodology - The base case valuation is derived from an average of P/E and DCF methodologies, with a calculated price target of A$10.30 based on a P/E relative of 20x for CY25e [8][9]. - The DCF analysis uses a WACC of 9.2% and a terminal growth rate of 3.5%, supporting the valuation outlook [9].

Core Insights - Innoviz Technologies Ltd. reported a quarterly loss of $0.05 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.18 per share a year ago, representing an earnings surprise of 37.50% [1] - The company posted revenues of $17.39 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.08%, but showing significant growth from $7.06 million in the same quarter last year [2] - Innoviz Technologies shares have declined approximately 39.9% since the beginning of the year, contrasting with a slight gain of 0.1% in the S&P 500 [3] Earnings Outlook - The earnings outlook for Innoviz Technologies is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.07 on revenues of $12.47 million, and for the current fiscal year at -$0.29 on revenues of $59.65 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Automotive - Original Equipment industry, to which Innoviz Technologies belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment and stock performance [5]

Core Viewpoint - Lucid Diagnostics Inc. reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking an earnings surprise of -77.78% [1][2] Financial Performance - The company posted revenues of $0.83 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 36.31%, compared to revenues of $1 million in the same quarter last year [2] - Over the last four quarters, Lucid Diagnostics has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Performance - Lucid Diagnostics shares have increased approximately 45.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.1% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $1.4 million, and for the current fiscal year, it is -$0.32 on revenues of $7 million [7] - The estimate revisions trend for Lucid Diagnostics is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Lucid Diagnostics belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Intellicheck Mobilisa, Inc. (IDN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.02 per share a year ago. These figures are adjusted ...

Group 1 - First Guaranty Bancshares (FGBI) reported a quarterly loss of $0.54 per share, significantly worse than the Zacks Consensus Estimate of $0.17, marking an earnings surprise of -417.65% [1] - The company posted revenues of $24.58 million for the quarter ended March 2025, slightly exceeding the Zacks Consensus Estimate by 0.07%, and showing an increase from $24.23 million year-over-year [2] - The stock has underperformed, losing about 15.4% since the beginning of the year, compared to a decline of -3.8% for the S&P 500 [3] Group 2 - The earnings outlook for First Guaranty Bancshares is mixed, with current consensus EPS estimates at $0.20 for the coming quarter and $0.89 for the current fiscal year [7] - The Zacks Industry Rank for Banks - Southeast is in the top 20% of over 250 Zacks industries, indicating a favorable environment for the sector [8] - First National Corp. is another company in the same industry, expected to report quarterly earnings of $0.53 per share, reflecting a year-over-year change of +3.9% [9]

Group 1 - Runway Growth Finance Corp. reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.36 per share, but down from $0.46 per share a year ago, representing an earnings surprise of 16.67% [1] - The company posted revenues of $35.4 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.84%, but down from $40.01 million year-over-year [2] - The stock has underperformed the market, losing about 16.8% since the beginning of the year compared to the S&P 500's decline of 3.8% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.36 on revenues of $33.2 million, and for the current fiscal year, it is $1.48 on revenues of $133.52 million [7] - The Financial - SBIC & Commercial Industry is currently ranked in the bottom 37% of over 250 Zacks industries, indicating a challenging outlook for the sector [8]

Group 1 - Enanta Pharmaceuticals reported a quarterly loss of $1.06 per share, slightly worse than the Zacks Consensus Estimate of a loss of $1.04, but an improvement from a loss of $1.47 per share a year ago, indicating an earnings surprise of -1.92% [1] - The company posted revenues of $14.93 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.71%, and down from $17.05 million in the same quarter last year [2] - Enanta Pharmaceuticals shares have declined approximately 8.4% since the beginning of the year, compared to a decline of 3.8% for the S&P 500 [3] Group 2 - The earnings outlook for Enanta Pharmaceuticals is mixed, with the current consensus EPS estimate for the upcoming quarter at -$1.15 on revenues of $16.34 million, and for the current fiscal year at -$3.90 on revenues of $64.44 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 27% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] - Plus Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of +77.3%, with revenues projected to be $1.85 million, up 10.1% from the previous year [9]

Core Insights - Blade Air Mobility, Inc. (BLDE) reported a quarterly loss of $0.04 per share, outperforming the Zacks Consensus Estimate of a loss of $0.11, and showing improvement from a loss of $0.06 per share a year ago [1] - The company achieved revenues of $54.31 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 9.55% and up from $51.51 million year-over-year [2] - Blade Air Mobility's shares have declined approximately 31.3% year-to-date, contrasting with the S&P 500's decline of 3.8% [3] Financial Performance - Over the last four quarters, Blade Air Mobility has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $65.57 million, and for the current fiscal year, it is -$0.17 on revenues of $256.96 million [7] Market Outlook - The earnings outlook for Blade Air Mobility is mixed, with a current Zacks Rank of 3 (Hold), indicating expected performance in line with the market [6] - The Technology Services industry, to which Blade Air Mobility belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - Montauk Renewables (MNTK) reported break-even quarterly earnings per share, matching the Zacks Consensus Estimate of $0.01, with a year-over-year comparison showing no change in earnings per share [1] - The company posted revenues of $42.6 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.14% and showing an increase from $38.79 million in the same quarter last year [2] - Montauk Renewables shares have declined approximately 43.7% year-to-date, contrasting with the S&P 500's decline of 4.3% [3] Earnings Outlook - The company's earnings outlook is uncertain, with current consensus EPS estimates at -$0.01 for the upcoming quarter and $0.06 for the current fiscal year, alongside projected revenues of $40.86 million and $181.79 million respectively [7] - The trend of estimate revisions for Montauk Renewables has been unfavorable, resulting in a Zacks Rank of 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Alternative Energy - Other industry, to which Montauk Renewables belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [8] - Comparatively, ReNew Energy Global PLC (RNW), another company in the same industry, is expected to report quarterly earnings of $0.07 per share, reflecting a year-over-year increase of 250% [9]

Sweetgreen, Inc. (SG) came out with a quarterly loss of $0.21 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Sweetgreen, which belongs to the Zack ...